Results 121 to 130 of about 2,061,642 (403)

Symptom Domain Groups of the Patient-Reported Outcomes Measurement Information System Tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis [PDF]

, 2017
Background Patient-Reported Outcomes Measurement Information System (PROMIS) tools can identify health-related quality of life (HRQOL) domains that could differentially affect disease progression.
Bajaj, Jasmohan S., Fagan, Andrew, Fuchs, Michael, Gavis, Edith A., Luketic, Velimir A., Matherly, Scott, Patidar, Kavish R., Puri, Puneet, Sanyal, Arun J., Siddiqui, Mohammad S., Sterling, Richard K., Stravitz, Richard T., Thacker, Leroy R., Wade, James B., White, Melanie B.   +14 more
core   +2 more sources

Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis

PLoS ONE, 2017
Background Sarcopenia is a common syndrome in chronic diseases such as liver cirrhosis. The association between sarcopenia and outcomes, such as complications and survival has recently been described in various patient groups.
Gaeun Kim, S. Kang, M. Kim, S. Baik
semanticscholar   +1 more source

Targeting Seipin to Alleviate Hepatic Steatosis in Zebrafish (Danio Rerio)

Advanced Science, EarlyView.
Seipin plays a crucial role in lipid metabolism. Seipin overexpression ameliorates high‐fat‐diet‐induced hepatic steatosis and enhances growth in zebrafish. Mechanistically, Seipin interacts with Plin2 to promote Plin2 degradation and enhances phosphatidylcholine synthesis via Seipin/CCTα/CHPT interactions.
Weijia Li, Yanan Shen, Zengqi Zhao, Baolin Li, Shunlang Wen, Rui Zhan, Qinghui Ai   +6 more
wiley   +1 more source

A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease

Nature Communications, 2019
The presence of cirrhosis in nonalcoholic-fatty-liver-disease (NAFLD) is the most important predictor of liver-related mortality. Limited data exist concerning the diagnostic accuracy of gut-microbiome-derived signatures for detecting NAFLD-cirrhosis ...
C. Caussy, A. Tripathi, G. Humphrey, Shirin Bassirian, Seema Singh, Claire S. Faulkner, R. Bettencourt, E. Rizo, L. Richards, Z. Xu, M. Downes, R. Evans, D. Brenner, C. Sirlin, R. Knight, R. Loomba   +15 more
semanticscholar   +1 more source

Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle‐Mediated Angiogenesis and the NF‐κB–PCLAF Signaling Axis

Advanced Science, EarlyView.
Clathrin Light Chain B (CLTB) drives hepatocellular carcinoma progression through dual pathways: intracellularly, it activates the NF‐κB–PCLAF axis to enhance small extracellular vesicle (sEV) uptake and tumor proliferation; extracellularly, CLTB‐enriched sEVs bind SH3KBP1 to inhibit its degradation, inducing angiogenesis and vascular leakage ...
Xiaoke Sun, Junchen Guo, Ning Zhao, Guanghua Cui, Yun Bai, Meijuan Ding, Yi Xu, Yu Yang   +7 more
wiley   +1 more source

Predictive model of in-hospital mortality in liver cirrhosis patients with hyponatremia: an artificial neural network approach

Scientific Reports
Hyponatremia can worsen the outcomes of patients with liver cirrhosis. However, it remains unclear about how to predict the risk of death in cirrhotic patients with hyponatremia. Patients with liver cirrhosis and hyponatremia were screened.
Zhaohui Bai, Yuhang Yin, Wentao Xu, Gang Cheng, Xingshun Qi   +4 more
doaj   +1 more source

Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis

Gastroenterology Research and Practice, 2019
Objective. The diagnostic value of antinuclear antibodies (ANAs) including anti-gp210 and anti-sp100 for primary biliary cholangitis/cirrhosis (PBC) has been widely reported.
Qian Zhang, Zhiqiang Liu, Shanshan Wu, Weijia Duan, Sha Chen, Xiaojuan Ou, Hong You, Yuanyuan Kong, Jidong Jia   +8 more
doaj   +1 more source

The incidence of portal vein thrombosis at liver transplantation [PDF]

, 1992
The incidence of portal vein thrombosis was examined in 885 patients who received orthotopic liver transplantations for various end‐stage liver diseases between 1989 and 1990. The thrombosis was classified into four grades.
Iwatsuki, S, Nonami, T, Starzl, TE, Yokoyama, I   +3 more
core   +1 more source

Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis

Canadian Journal of Gastroenterology and Hepatology, 2018
Liver cirrhosis is a major cause of mortality and a common end of various progressive liver diseases. Since the effective treatment is currently limited to liver transplantation, stem cell-based therapy as an alternative has attracted interest due to ...
Kyeong-Ah Kwak, Hyun-Jae Cho, Jin-Young Yang, Young-Seok Park   +3 more
semanticscholar   +1 more source

Inhaling Eugenol Inhibits NAFLD by Activating the Hepatic Ectopic Olfactory Receptor Olfr544 and Modulating the Gut Microbiota

Advanced Science, EarlyView.
Inhalable eugenol (EUG) from clove oil attenuates NAFLD by activating hepatic olfactory receptor Olfr544, triggering cAMP/PKA/CREB signaling to enhance lipolysis/oxidation. EUG concurrently restores gut microbiota, enriching probiotics (L. reuteri XR23/L. johnsonii XR25) and metabolites (IPA/5‐HIAA) that suppress lipogenesis.
Xiao‐Ran Wang, Zhan‐Zhan Li, Shu‐Ding Sun, Ya‐Gang Song, Jin‐Xin Miao, Xiang‐Xiang Wu, Yong‐Li Han, Xiao‐Lei Zhang, Wen‐Jing Chen, Qing‐Hua Wang, Yu Zhang, Yiping Fu, Yu‐ting Liu, Lin‐yan Lang, Wen‐Xia Zhao, Ming‐San Miao   +15 more
wiley   +1 more source